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Abstract
Gene therapy appears as a promising strategy to treat 
incurable diseases. In particular, combined gene therapy 
has shown improved therapeutic efficiency. Internal 
ribosome entry sites (IRESs), RNA elements naturally 
present in the 5’ untranslated regions of a few mRNAs, 
constitute a powerful tool to co-express several genes 
of interest. IRESs are translational enhancers allowing 
the translational machinery to start protein synthesis 
by internal initiation. This feature allowed the design of 
multi-cistronic vectors expressing several genes from a 
single mRNA. IRESs exhibit tissue specificity, and drive 
translation in stress conditions when the global cell 
translation is blocked, which renders them useful for 
gene transfer in hypoxic conditions occurring in ischemic 
diseases and cancer. IRES-based viral and non viral 
vectors have been used successfully in preclinical and 
clinical assays of combined gene therapy and resulted 
in therapeutic benefits for various pathologies including 
cancers, cardiovascular diseases and degenerative 
diseases. 
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Core tip: Combined gene therapy has emerged for a few 
years as a promising strategy to improve treatments of 
many diseases including cancer, cardiovascular diseases 
and degenerative diseases. In this context, internal 
ribosome entry site (IRES)-based vectors provide a 
powerful system to co-express several therapeutic genes 
from the same transcription unit. IRESs are translational 
enhancers, exhibiting tissue-specificity, and activated 
by stress. Different IRES-based vectors including 
plasmids, adeno-associated virus-derived and lentiviral 
vectors have been used successfully in many preclinical 
protocols of gene therapy. Moreover the few clinical 
assays launched with IRES-based multicistronic vectors 
resulted in therapeutic benefits.
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INTRODUCTION
Combined gene therapy has appeared for a few years as an 
attractive approach to optimize the therapeutic benefits 
of  gene transfer. In the field of  cancer, the first examples 
of  antitumoral cooperative effect have been provided 
by co-expression of  the co-stimulation molecules CD70 
and CD80, and of  the two anti-angiogenic factors, 
angiostatin and endostatin, respectively[1-4]. Synergistical 
effects have also been obtained with co-expression 
of  angiogenic growth factors generating therapeutic 
angiogenesis in ischemic diseases. This rational has 
been proven first with co-administration of  vascular 
endothelial growth factor A (VEGFA) and angiopoietin 
as recombinant proteins as well as by co-administration 
of  two plasmids coding these growth factors[5]. A few 
years later, combination of  recombinant fibroblast growth 
factor 2 (FGF2) and PDGF-B also improved hindlimb 
ischemia in rats whereas a bicistronic vector expressing 
FGF2 and VEGFA efficiently induced vessel formation 
in a mouse angiogenesis assay[6,7]. These studies launched 
the concept of  combined biotherapy. They also revealed 
that combined gene therapy is a promising therapeutic 
approach, allowing long term efficiency of  treatments 
compared to recombinant proteins whose half  life is often 
very short. 
Internal ribosome entry sites (IRESs) are translational 
enhancers naturally present in a series of  mRNAs, 
mediating internal initiation of  translation when present 
between the genes of  interest (Figure 1). IRESs thus 
allow the design of  multicistronic expression cassettes 
resembling bacterial operons, able to drive translation 
of  several genes coded by the same mRNA[8]. We have 
demonstrated that the use of  IRES-based vectors co-
expressing two genes of  interest allows stable transgene 
expression with a constant ratio of  the proteins of  
interest, in contrast to the use of  two different plasmids 
expressing each transgene[9]. Actually, a bicistronic IRES-
based vector co-expressing FGF2 and Cyr61 has revealed 
more efficient to generate therapeutic angiogenesis at 
low doses than the monocistronic vectors expressing 
large amounts of  only one of  these angiogenic factors[10]. 
It must be underlined that the IRES-based vector had 
no side effects on promotion of  tumoral angiogenesis 
in contrast to the monocistronic ones, a very important 
feature for increased safety in clinical assays. These 
observations prompted us to deepen the features of  
IRESs applicable to vectorology and assess progress made 
in the field of  gene transfer and combined gene therapy 
clinical assays using IRES-based vectors. 
IRESS, TRANSLATIONAL ACTIVATORS 
FOR COMBINED TRANSGENE 
EXPRESSION
At a time when it was admitted that initiation of  translation 
in eukaryotes required recognition of  the capped mRNA 
5’ end to recruit ribosomes, translation of  the uncapped 
picornavirus mRNAs from an internal start codon 
remained a mystery. Indeed, the so-called ribosome 
scanning mechanism predicted that ribosomes bound to 
the mRNA 5’ end scanned the mRNA molecules until 
they recognized an AUG codon[11,12] (Figure 1). The event 
of  internal ribosome binding was thought impossible. 
This puzzle raised by picornaviruses was solved by the 
discovery of  RNA elements, called IRES, present in the 
5’ untranslated regions of  their mRNAs, which allow 
internal recruitment of  ribosomes[13,14]. The dogma of  the 
scanning mechanism was thus broken. In addition, it was 
quickly extended to cellular mRNAs as the first cellular 
IRES was discovered three years later in the BiP mRNA, 
coding for the immunoglobulin chaperone also known as 
GRP78[15]. This discovery was followed by the finding of  
several other IRESs in cellular mRNAs, in particular in 
the mRNAs of  angiogenic growth factors such as FGF2, 
proto-oncogenes such as c-myc, pro and anti-apoptotic 
proteins such as X chromosome-linked inhibitor-of-
apoptosis protein and apoptotic peptidase activating 
factor 1[16-20]. IRESs were also found in retroviruses, 
whose mRNAs are capped as cellular mRNAs, leading to 
the design of  IRES-containing retroviral vectors[21,22].
The existence of  IRESs in capped cellular mRNAs 
asked the question of  their pathophysiological function[23]. 
Actually, several reports showed that IRESs from cellular 
mRNAs are regulated in various physiological processes 
including cell differentiation, spermatogenesis, neurone 
plasticity[24-27]. Several IRESs are also activated during cell 
cycle mitosis[28,29]. Recent reports have also shown that 
IRESs are aberrantly activated in tumor cells, and are thus 
involved in dysregulation of  gene expression in cancer[30]. 
Furthermore, cellular IRES activity is stimulated in stress 
conditions such as apoptosis and hypoxia when cap-
dependent translation is blocked[31-36].
IRES-dependent internal initiation of  translation 
reminds the prokaryotic initiation mechanism which can 
translate polycistronic mRNAs[37,38]. This observation 
gave the idea that such operons could be created in 
eukaryotes using IRESs to design expression vectors[39]. A 
large majority of  expression vectors allow co-expression 
of  two genes under the control of  two promoters. 
However such an approach has revealed that one of  the 
genes may be silenced despite of  the expression of  the 
other one even though it expresses an antibiotic[40]. This 
can result from competition between the two promoters or 
counterselection of  the gene of  interest in case of  toxicity 
or of  cell growth inhibition. In such a context, IRESs have 
been used to generate transgene co-expression under the 
control of  a single promoter (Figure 2).
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The first retroviral tricistronic IRES-based vector 
appeared in 1992, providing an exciting potential for 
gene therapy[41]. This vector successfully co-expressed 
adenosine desaminase with neomycin (NEO) resistance 
and chloramphenicol acetyltransferase reporter genes, 
using the two picornavirus IRESs from poliovirus and 
encephalomyocarditis virus (EMCV), respectively. Two years 
later, a therapeutic tricistronic vector expressing the two 
interleukin-12 subunits with NEO validated the concept of  
IRES-based vectors to co-express two subunits of  a protein 
with an adequate stoechiometry together with a resistance 
gene[42]. In the following years, bicistronic vectors were used 
successfully to select cell clones expressing a protein of  
interest with a resistance gene, preventing the problems 
generated by the use of  two promoters[40,43]. 
TISSUE-SPECIFICITY OF CELLULAR 
IRESS
Most IRES-based vectors developed up to now use 
picornavirus IRESs, based on the strong efficiency 
of  such IRESs in transient transfection, compared to 
cellular IRESs. It has been observed that cellular IRESs 
often exhibit a low efficiency in transiently transfected 
cells. Such a feature may result from the cell and tissue 
specificity of  the cellular IRES activities. Actually, the 
FGF2 IRES activity varies with the cell type, the lowest 
being in fibroblasts, and the highest in neuroblastoma 
and osteosarcoma cells[44]. Similar variations have been 
observed for other cellular IRESs[45] (Creancier L and 
Prats AC, unpublished results). The strongest regulation 
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Figure 1  Cap-dependent and internal ribosome entry 
site-dependent initiation, two alternative mechanisms 
of translation. A: The so-called cap-dependent ribosome 
scanning mechanism predicts that ribosome 40S subunit 
binds to the mRNA 5’ end. Ribosome binding requires the 
initiation factor 4F (eIF-4F, composed of the three proteins 
eIF-4E, -4A and -4G). Then the mRNA is unwound under 
the control of the helicases eIF-4A and -4B, allowing the 
ribosome to scan the mRNA until recognition of an initiation 
codon (classically AUG)[11,12]; B: When an Internal ribosome 
entry site (IRES) is present in the mRNA 5’ untranslated 
region, IRES trans-acting factors (ITAFs) allow ribosome 
40S internal recruitment, independently of the presence of 
cap and eIF-4F. The IRES-dependent mechanism occurs in 
the case of picornavirus uncapped mRNAs as well as for 
cellular capped mRNAs.
Figure 2  Internal ribosome entry site-based multicis-
tronic vector concept. The internal ribosome entry site 
(IRES)-based expression cassette contains several genes, 
separated by IRESs, under the control of the same promoter 
(Pr). This transcription unit gives rise to a single mRNA 
coding the different genes. Translation initiation occurs 
at the 5’ end by the cap-dependent mechanism, resulting 
in translation of the first open reading frame (ORF, Gene 
A ). Internal initiations of translation occur at each IRES, 
resulting in translation of the other ORFs (Genes B  and C ). 
Thus the multicistronic mRNA generates several proteins 
from a single transcription unit, allowing more stable long 
term expression and stable transgene ratio[9,48]. For each 
ORF, initiation (AUG) and termination (STOP) codons are 
indicated.
A B
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1α (HIF1α), the key of  the cell response to hypoxia that 
induces transcription of  all the genes containing a hypoxia 
responsive element (HRE) in their promoters[51]. This 
IRES allows HIF mRNA translation to be activated during 
hypoxia despite of  the blockade of  global translation[32,52]. 
Such activation occurs under the control of  an ITAF, the 
pyrimidine tract binding protein, also known as a regulator 
for various IRESs[52,53].
An important consequence of  hypoxia is the stimulation 
of  angiogenesis in order to generate new vessels able to 
restore the cell supply with oxygen. This process occurs in 
cancers when cells in the tumor core are oxygen deprivated, 
as well as in ischemic diseases such as heart and lower 
limb ischemia when tissues are not any more irrigated 
due to artery occlusion. Strikingly, the major angiogenic 
factors VEGFA (vascular endothelial growth factor A), 
FGF1 and FGF2, possess IRESs in their mRNAs[20,47,54-56]. 
VEGFA expression, transcriptionally induced by HIF1α, 
is also translationally enhanced via the IRES in hypoxic 
tumors and in ischemic mouse legs[31,32,36]. In contrast 
to VEGFA, FGF2 is not induced transcriptionally by 
hypoxia but its synthesis is translationally induced by 
the IRES-dependent mechanism in ischemic tissues[31,33]. 
The same phenomenon has been observed for the major 
lymphangiogenic factor VEGFC, induced by hypoxia 
at the translational level via an IRES, but not at the 
transcriptional level, in tumors and lymph nodes[36,57]. 
FGF2 and VEGFC induction is exclusively translational 
and HIF-independent, revealing that IRESs provide an 
alternative HIF-independent way of  response to hypoxia.
On a biotechnological point of  view, the sensitivity 
of  IRESs to hypoxia may be an advantage for several 
applications. Gene transfer vectors can benefit from 
this feature as the presence of  IRESs allows increased 
transgene expression in ischemic conditions in vivo. Once 
again, one can see that data from basic research have 
to be taken into account in the design of  optimized 
expression cassettes. The use of  IRES-based vectors seems 
particularly adequate for gene therapy of  ischemic diseases 
and cancer, as in both cases the transgenes have to be 
expressed in hypoxic conditions.
BIOMEDICAL APPLICATIONS OF IRESS
IRESs have found biomedical applications for several 
years. As mentioned above, the first biomedical use of  
IRESs in an expression vector has been co-expression 
of  subunits of  a therapeutic protein with a gene of  
resistance, as shown for interleukin 12 subunits with a 
gene of  resistance[42]. However this application is limited 
to therapeutic genes composed of  several subunits. In 
addition, the use of  resistance genes is not recommended 
as it may prevent the use of  the vector in a clinical assay. 
Another application of  IRESs raised during the 
last decade, resulting form the emerging concept of  
combined gene therapy. Several studies have validated 
this concept using a cocktail of  two vectors to transfer 
two genes simultaneously. This has been particularly 
of  cellular IRESs has been shown in vivo, in transgenic 
mice expressing bicistronic dual luciferase constructs 
containing different IRESs. Clearly, the EMCV IRES was 
active in most tissues and organs, while the FGF2 IRES 
was very low in most organs except for testis and brain 
where its activity increased 200 to 400 times, at least 10 
times higher than the EMCV IRES activity[44]. A similar 
behavior was observed with other cellular IRESs such as 
c-myc and VEGFA IRESs[31,45].
The tissue-specific features of  cellular IRESs are 
useful to control transgene expression. Thus they can 
be considered as translational enhancers, if  one makes 
a parallel with transcriptional enhancers upstream of  
promoters, governing the tissue-specificity of  gene 
expression. The concept of  translational tissue-specificity 
may be applied to gene transfer by coupling tissue-specific 
IRESs with tissue-specific promoters to create vectors 
with increased safety. This concept should also remember 
us that EMCV is not always the best IRES to be used. 
A recent study reports the failure of  expression of  the 
second cistron of  a bicistronic adeno-associated virus 
(AAV) vector using the EMCV IRES, in murine cerebellar 
Purkinje neurons[46]. 
The advantage of  using a cellular IRES has also been 
demonstrated for gene transfer into skeletal muscle. The 
FGF1 IRES is as efficient as the EMCV IRES in mouse 
muscle after plasmid DNA electrotransfer[47]. Moreover, 
when this IRES is used in a bicistronic AAV vector, its 
activity is significantly superior to that of  the EMCV 
IRES in myoblasts and allows a transgene expression 10 
times more efficient when this AAV is injected in mouse 
muscle[48]. Such a difference may be due to the presence 
of  specific FGF1 IRES trans-acting factors (ITAFs) 
(Ainaoui et al, in revision). Alternatively, it can result 
from the lower ability of  the EMCV IRES to maintain a 
stable long term compared to cellular IRESs, shown in a 
previous report[9].
On the basis of  these different data, it can be 
recommended to choose the adequate IRES to be used 
according to the cell type or tissue to be targeted, rather 
than using systematically the EMCV IRES as presently 
proposed in all commercial IRES-based vectors.
IRES-MEDIATED GENE EXPRESSION IN 
STRESS CONDITIONS
In many diseases cells are subjected to different stresses 
such as hypoxia, apoptosis or ER stress. In stress conditions, 
translation initiation is inhibited by two ways: blockade the 
mammalian target of  rapamycin pathway which affects 
ribosome recruitment on the cap, and phosphorylation 
of  eIF2-α which prevents charged initiator Met-tRNA 
formation. Interestingly, IRES-dependent translation is not 
affected by these two ways of  silencing[35,49,50]. 
As mentioned above, IRESs are naturally present in 
messenger RNAs coding for proteins involved in the stress 
response, especially apoptosis and hypoxia. In particular, an 
IRES is present in the mRNA of  the hypoxia-induced factor 
14
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documented in the field of  cardiovascular diseases and 
cancer, with therapeutic benefits obtained in different 
animal models using different combinations of  angiogenic 
or anti-angiogenic factors[4,5,58-61] (Table 1). Interestingly 
the combination of  VEGFA and PDGFB successfully 
induced therapeutic angiogenesis both in ischemic leg and 
in ischemic heart. In the field of  rare diseases, two AAV 
vectors expressing microdystrophin and IGF1 resulted 
in increased muscle mass and strength, reduced myofiber 
degeneration and increased protection against contraction-
induced injury in mdx mice[62]. These different studies were 
performed either with naked DNA or with recombinant 
adeno-associated virus vectors. 
The use of  two different vectors for multiple transgene 
expression exhibits disadvantages: on the one hand, the 
ratio of  the therapeutic molecules cannot be controlled, 
leading in the loss of  the cooperative effect: expression 
of  one of  the vectors often decrease or is silenced earlier 
than the other one[40]. On the other hand, the cost of  two 
therapeutic vectors in a clinical perspective is higher than 
a single one. These disadvantages are still more important 
in case of  a cocktail of  three or more therapeutic genes.
The concept of  IRES-based vectors for combined gene 
therapy has been validated for combined immunotherapy 
of  cancer using a tricistronic retrovirus expressing the 
two co-stimulation molecules CD70 and CD80[2] (Table 
2). In addition to the EMCV IRES, several cellular or 
retroviral IRESs were successful in this approach[63]. In vivo 
gene therapy has also been validated for the treatment of  
ischemic limb in a mouse model, following intramuscular 
injection and electrotransfer of  a plasmid containing the 
FGF1 IRES for co-expression of  FGF2 and Cyr61[10]. This 
study showed than the two angiogenic factors, although 
expressed at lower doses from the bicistronic vector than 
from the monocistronic ones, have a synergistical effect 
in stimulating therapeutic angiogenesis, rendering the 
bicistronic construct more efficient. More importantly, due 
to the lower doses of  therapeutic molecules, the bicistronic 
vector induces no side effects on tumoral angiogenesis, in 
contrast to one of  the monocistronic vectors expressing 
huge amounts of  Cyr61. Thus combined gene therapy 
using IRES-based vectors is also a safer therapeutic 
approach.
Additional studies have confirmed the successful use 
of  IRES-based vectors for combined treatment of  limb 
ischemia with VEGFA and FGF4 or bone morphogenetic 
protein7 (BMP7)[64,65]. Combined gene therapy of  cancer 
was also reported using IRES-based vectors co-expressing 
IL-12 and CD80, as well as antiangiogenic factors 
angiostatin and endostatin, or CXCL4I and fibstatin[66-69] 
(Table 2). Combination of  angiostatin and endostatin in 
an IRES-based vector was also successful to treat age-
related macular degeneration in a mouse model[70]. In the 
field of  degenerative diseases, mucopolysaccharidosis 
type ⅢA has been addressed in presymptomatic MPSⅢ
A mice by intrastriatal administration of  an AAV vector 
co-expressing N-sulfoglycosamine sulfohydrase (SGSH) 
with the sulfatase-modifying factor (SUMF1) (Winner 
et al, submitted). This study has resulted in a clinical 
assay[71] see below). Only one report has obtained better 
data with two separate AAV vectors to deliver FGF14 
and a fluorescent protein into purkinje neurons, than with 
an IRES[46]. This study used the EMCV IRES previously 
reported to function in neurons[72]. However it must 
be underlined that the EMCV IRES is not very active in 
neurons in vivo, by comparison with the FGF2 IRES that is 
at least ten times more active[24,44]. In such a case, one can 
expect that the choice of  the FGF2 IRES would provide 
better data. 
Multigene transfer has also been validated for combina-
tions of  three genes. A tricistronic IRES-based lentivector 
expressing three catecholaminergic proteins, Prosavin, was 
administrated by bilateral striatal injection for treatment 
of  Parkinson in rats, resulting in important therapeutic 
benefits[73,74] (Table 2). Moreover, a tricistronic 2A-based 
lentivector administrated in situ was also efficient in co-
expressing Gata4, Mef2c and Tbx5 for postinfarct ventricular 
functional improvement in rats[75]. 
It is often mentioned that the IRES-driven translation 
of  the downstream cistrons is lower than the cap-
dependent first cistron translation. This issue can easily 
be addressed by intelligent vector design: First, one can 
take into account the tissue specificity of  the IRES by 
choosing the most adequate IRES rather than using 
systematically the EMCV IRES. Most bi- and- tricistronic 
vectors use this IRES although it is far to be the best one 
15
  Pathology Therapeutic genes   Animal model  Vector type  Ref.
  Cancers
     Leukemia, melanoma Angiostatin + endostatin Mouse Retrovirus Scappaticci et al[4], 2001
     Ovarian cancer Angiostatin + endostatin Mouse AAV Ponnazhagan et al[3], 2004
     Glioblastoma VEGF-R1 + angio-endo (Statin AE) Mouse SB transposon Ohlfest et al[60], 2005
     Pancreatic cancer TSP1 + endostatin Mouse AAV Zhang et al[61], 2007 
  Cardiovascular diseases
     Limb ischemia  VEGFA + angiopoietin-1 Rabbit Plasmid Chae et al[5], 2000
     Limb ischemia  VEGFA + FGF2 Mouse Plasmid Lee et al[59], 2007
     Limb ischemia  VEGFA + PDGFB Rabbit AAV Kupatt et al[58], 2010
     Heart ischemia VEGFA + PDGFB Pig AAV Kupatt et al[58], 2010
  Rear diseases
     DMD Microdystrophin + IGF1 Mouse AAV Abmayr et al[62], 2005
Table 1  Preclinical studies of combined gene therapy with co-administration of monocistronic vectors
DMD: Duchenne muscular dystrophy; VEGF: Vascular endothelial growth factor; FGF2: Fibroblast growth factor 2; AAV: Adeno-associated virus.
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in many tissues such as muscle or brain[24,48]. Second, the 
IRES efficiency can be improved. It must be noticed that 
the EMCV IRES activity is very sensitive to the position 
of  the start codon of  the gene of  interest. This IRES, 
in contrast to the FGF1 IRES, exhibits no flexibility: 
the AUG must be positioned just downstream from the 
IRES. The insertion of  a single restriction site between 
the IRES and the AUG codon is sufficient to inactivate 
the IRES[76]. The insertion of  a spacer between the first 
gene and the IRES is also susceptible to enhance the IRES 
activity by preventing IRES structural alterations by RNA 
sequences located upstream[77]. In addition, mutations of  
the upstream AUG codons in the EMCV IRES improve 
its efficiency[78]. Finally, an important parameter is the IRES 
regulation by microenvironment. In particular, FGF or 
VEGF IRES activities are more sensitive to hypoxia than 
the EMCV IRES and may allow a more efficient transgene 
expression in ischemic diseases.
ALTERNATIVES TO IRESS FOR 
MULTICISTRONIC VECTORS
IRES-based vectors are not the only approach to co-
express several gene products under the control of  a 
single promoter. The first alternative is gene fusion. It 
has been successfully used to combine endostatin and 
angiostatin in a treatment of  melanoma and of  head and 
neck cancer[79,80]. A second alternative to IRESs is the use 
of  alternative splicing-based vectors. Such an approach 
had been proposed many years ago using retroviral 
vectors, using the natural alternative splicing features of  
retrovirus genome[81,82]. This concept has been developed 
more recently in the purpose of  co-expressing two 
immunoglobulin chains[83]. The interest of  this system is the 
ability to adapt the ratio of  the two transgenes by mutating 
the splicing sites. However one limit of  this attractive 
system is that splicing site efficiency and consequently 
the ratio of  the two proteins of  interest, is influenced by 
the presence of  exon splicing enhancers or silencers in 
the transgene sequences, preventing the design of  vectors 
with a stable transgene ratio applicable to co-expression 
of  any pair of  therapeutic proteins. 
A third exciting system of  co-expression is provided 
by the 2A peptides. Such peptides, occurring in many 
viral genomes, are peptide sequences of  about 19 amino-
acid residues, which can produce a discontinuity in the 
translated polypeptide when encoded in a longer open 
reading frame (ORF)[84]. In contrast to what is currently 
admitted, 2A peptides do not catalyze a protein cleavage, 
but they catalyze termination of  translation in the 
absence of  a stop codon, followed by reinitiation. They 
are currently used as a tool to co-express two or more 
separate proteins from a single ORF[85]. 2A peptides 
thus constitute an alternative to IRESs, but do not 
work in all systems. By example, in the study in purkinje 
neurons mentioned above, a 2A peptide was used but 
did not function, resulting in detection of  the longer 
ORF rather than the two expected proteins[46]. In another 
report comparing bicistronic constructs expressing Sox9 
and EGFP separated by the EMCV IRES or by the 
FMDV 2A peptide, the authors detected 42% of  Sox-
EGFP fusion protein, reflecting an inefficient ribosome 
skipping mechanism[86]. Formation of  such fusion proteins 
often occurs with proteins bearing N-terminal signal 
sequences[87]. In addition, no information is available about 
the 2A peptides tissue-specificity or behavior in response 
to stress, in contrast to IRESs.
CLINICAL APPLICATIONS OF IRES-
BASED VECTORS TO GENE THERAPY
All the preclinical studies mentioned above show that 
16
  Pathology Therapeutic genes Animal model IRES Vector type  Ref.
  Cancers
     Fibrosarcoma CD70 + CD80 Mouse EMCV Retrovirus Couderc et al[2], 1998
     Melanoma Angio-endo fusion Mouse None (fusion) Retrovirus Scappaticci et al[79], 2001
     Multiple myeloma IL12 subunits + CD80 Mouse EMCV + FMDV Retrovirus Wen et al[69], 2001; Li et al[67], 2003
     Melanoma CD70 + CD80 Mouse EMCV, c-myc, FGF2, 
HTLV1
Retrovirus Douin et al[63], 2004
     Ovarian cancer   Angiostatin + endostatin Mouse EMCV AAV Isayeva et al[66], 2005
     Head and neck cancer Angio-endo fusion Mouse None (fusion) Vaccinia virus Tysome et al[80], 2011
     Pancreas cancer CXCL4L1 + fibstatin Mouse FGF1 AAV, 
Lentivector
Prats et al[68], 2013
  Cardiovascular diseases
     Limb ischemia FGF2 + Cyr 61 Mouse FGF1 Plasmid Rayssac et al[10], 2009
     Limb ischemia VEGFA + BMP7 Rabbit EMCV AAV Zhang et al[65], 2010
     Limb ischemia VEGFA + FGF4 Mouse EMCV AAV Jazwa et al[64], 2013
     Heart ischemia Gata4 + Mef2C + Tbx5 Rat None (2A element) Lentivector Mathison et al[75], 2014
  Neurodegenerative diseases
     Parkinson TH + AADC + CH1 Rat EMCV Lentivector  Azzouz et al[73], 2002
Stewart et al[74], 2011
     AMD Angiostatin + endostatin Mouse EMCV Lentivector  Kachi et al[70], 2009
Table 2  Preclinical studies of combined gene therapy using multicistronic vectors
BMP7: Bone morphogenetic protein 7; Gata4: GATA binding protein 4; Mef2C: Myocyte-specific enhancer factor 2C; Tbx5: T-box transcription factor 5; TH: 
Tyrosine hydroxylase; AADC: aromatic L-amino acid decarboxylase; CH1: GTP cyclohydrolase-1; AMD: Age-related macular degeneration.
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IRES-based vectors represent an exciting tool to be used 
for combined gene therapy. Nowadays, very little clinical 
trials with such vectors have been reported. The first trial 
to be cited is the tricistronic IL12-expressing retrovirus, 
which gave significant decrease of  tumor sizes on a few 
patients with melanoma or head and neck cancer[88,89]. 
A bicistronic IRES-based vector co-expressing FGF2 
and VEGFA has been assessed in a clinical assay of  gene 
therapy on patients with refractory coronary disease[90] 
(Table 3). The protocol corresponded to intramyocardial 
transfer of  a plasmid expressing the bicistronic cassette. This 
study showed no improvement in myocardial perfusion, 
but treated patients exhibited improved exercice tolerance 
and clinical symptoms. Furthermore the bicistronic 
gene transfer was safe. This moderate benefit, although 
encouraging, may be due to the use of  a plasmid, which 
does not provide long term expression in contrast to 
viral vectors, and also to the choice of  the EMCV IRES 
which is not optimal to drive gene expression in hypoxic 
conditions[31,36].
Very recently, two gene therapy clinical trials successfully 
used multi-cistronic IRES-based viral vectors. On the one 
hand, a gene therapyⅠ/Ⅱ phase clinical trial on patients 
with mucopolysaccharidosis type ⅢA, a severe degenerative 
disease, has displayed neurocognitive benefits[71]. Four 
children received intracerebral injections of  a bicistronic 
AAV vector expressing the SGSH and SUMF1 genes 
separated by the EMCV IRES. Neurocognitive evaluations 
suggest a cognitive benefit on the youngest patient, where 
as the other ones are stabilized. Importantly, the treatment 
was safe and well tolerated after 1 year in all the patients, 
validating the surgical approach for direct AAV delivery 
in the brain parenchyma. On the other hand, a phaseⅠ/Ⅱ 
assay was performed on 15 patients with Parkinson’s disease 
using Prosavin (see above), a tricistronic lentivector with 
EMCV IRESs administrated by intrastriatal delivery[91]. A 
significant improvement of  motor scores was recorded in all 
patients at 6 mo. This is the first-in-man use of  a lentiviral-
based gene therapy vector for a neurodegenerative disease. 
These studies validate the clinical use of  IRES-based viral 
vectors.
CONCLUSION
Many reports have shown that combined gene therapy is 
an attractive approach in animal models. This observation 
has justified extensive research on optimization of  gene 
transfer vectors able to co-express several proteins. In this 
context, IRES-based vectors have now been validated in 
pre-clinical as well as in clinical studies by showing their 
safety and ability to generate therapeutic benefits.
In addition, the data available on IRES tissue-specificity 
and activation in response to stress provide promising 
perspectives of  vector improvement, which may result in 
better efficiency of  gene therapy.
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